First Trust Advisors LP Has $658,000 Position in Chemed Corp. (CHE)

First Trust Advisors LP decreased its position in Chemed Corp. (NYSE:CHE) by 12.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,257 shares of the company’s stock after selling 477 shares during the quarter. First Trust Advisors LP’s holdings in Chemed were worth $658,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of CHE. Strs Ohio raised its holdings in Chemed by 305.3% during the third quarter. Strs Ohio now owns 7,700 shares of the company’s stock worth $1,555,000 after purchasing an additional 5,800 shares in the last quarter. APG Asset Management N.V. purchased a new position in shares of Chemed during the third quarter worth approximately $5,657,000. Rockefeller Financial Services Inc. grew its position in shares of Chemed by 6.0% during the third quarter. Rockefeller Financial Services Inc. now owns 86,192 shares of the company’s stock worth $17,415,000 after acquiring an additional 4,844 shares during the last quarter. Mutual of America Capital Management LLC grew its position in shares of Chemed by 100.0% during the third quarter. Mutual of America Capital Management LLC now owns 22,922 shares of the company’s stock worth $4,631,000 after acquiring an additional 11,459 shares during the last quarter. Finally, Shell Asset Management Co. grew its position in shares of Chemed by 173.1% during the third quarter. Shell Asset Management Co. now owns 28,994 shares of the company’s stock worth $2,983,000 after acquiring an additional 18,379 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have recently issued reports on the stock. National Bank Financial upgraded shares of Chemed from a “sector perform market weight” rating to an “outperform market weight” rating in a research report on Sunday, August 13th. Royal Bank Of Canada restated a “hold” rating and set a $209.00 target price on shares of Chemed in a research report on Tuesday, October 3rd. Zacks Investment Research lowered shares of Chemed from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. ValuEngine lowered shares of Chemed from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, KeyCorp started coverage on shares of Chemed in a research report on Monday, August 28th. They set a “sector weight” rating on the stock. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $236.00.

Chemed Corp. (CHE) opened at $237.92 on Friday. Chemed Corp. has a 1 year low of $151.23 and a 1 year high of $251.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48. The firm has a market cap of $3,813.16, a price-to-earnings ratio of 29.41, a P/E/G ratio of 5.05 and a beta of 1.16.

Chemed (NYSE:CHE) last posted its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share for the quarter, beating analysts’ consensus estimates of $2.00 by $0.15. Chemed had a net margin of 4.62% and a return on equity of 27.69%. The firm had revenue of $417.40 million for the quarter, compared to analyst estimates of $414.34 million. During the same period last year, the firm posted $1.73 EPS. Chemed’s quarterly revenue was up 6.3% on a year-over-year basis. equities analysts anticipate that Chemed Corp. will post 4.73 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Monday, December 4th. Shareholders of record on Monday, November 13th were given a dividend of $0.28 per share. The ex-dividend date of this dividend was Friday, November 10th. This represents a $1.12 annualized dividend and a dividend yield of 0.47%. Chemed’s payout ratio is currently 24.89%.

In other news, VP Naomi C. Dallob sold 750 shares of Chemed stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $222.09, for a total transaction of $166,567.50. Following the completion of the transaction, the vice president now owns 9,097 shares of the company’s stock, valued at approximately $2,020,352.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Patrick P. Grace sold 500 shares of Chemed stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $201.48, for a total value of $100,740.00. Following the transaction, the director now directly owns 4,515 shares of the company’s stock, valued at approximately $909,682.20. The disclosure for this sale can be found here. Insiders have sold a total of 46,179 shares of company stock worth $10,729,699 over the last 90 days. Insiders own 4.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://weekherald.com/2017/12/08/first-trust-advisors-lp-has-658000-position-in-chemed-corp-che.html.

Chemed Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply